HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, H. Articles by Tien, P. Search for Related Content PubMed PubMed Citation Articles by Li, H. Articles by Tien, P.

Generation of Murine CTL by a Hepatitis B Virus-Specific Peptide and Evaluation of the Adjuvant Effect of Heat Shock Protein Glycoprotein 96 and Its Terminal Fragments¹

Hongtao Li^*,, Minghai Zhou^*,, Jinle Han^*, Xiaodong Zhu^*,, Tao Dong, George F. Gao^2,*, and Po Tien^2,*

^* Department of Molecular Virology, Institute of Microbiology, Chinese Academy of Sciences, and Graduate School of the Chinese Academy of Sciences, Beijing, Peoples Republic of China; and Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

Previously, we reported that a 7-mer HLA-A11-restricted peptide (YVNTNMG) of hepatitis B virus (HBV) core Ag (HBcAg_88–94) was associated with heat shock protein (HSP) gp96 in liver tissues of patients with HBV-induced hepatocellular carcinoma (HCC). This peptide is highly homologous to a human HLA-A11-restricted 9-mer peptide (YVNVNMGLK) and to a mouse H-2-K^d-restricted 9-mer peptide (SYVNTNMGL). To further characterize its immunogenicity, BALB/c mice were vaccinated with the HBV 7-mer peptide. It was found that a specific CTL response was induced by the 7-mer peptide, although the response was 50% of that induced by the mouse H-2-K^d-restricted 9-mer peptide, as detected by ELISPOT, tetramer, and ⁵¹Cr release assays. To evaluate the adjuvant effect of HSP gp96, mice were coimmunized with gp96 and the 9-mer peptide, and a significant adjuvant effect was observed with gp96. To further determine whether the immune effect of gp96 was dependent on peptide binding, the N- and C-terminal fragments of gp96, which are believed to contain the putative peptide-binding domain, were cloned and expressed in Escherichia coli. CTL assays indicated that only the N-terminal fragment, but not the C-terminal fragment, was able to produce the adjuvant effect. These results clearly demonstrated the potential of using gp96 or its N-terminal fragment as a possible adjuvant to augment CTL response against HBV infection and HCC.

This article has been cited by other articles:

				X. Gong, W. Gai, J. Xu, W. Zhou, and P. Tien Glycoprotein 96-Mediated Presentation of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human Leukocyte Antigen Class I-Restricted Peptide and Humoral Immune Responses to HIV-1 p24 Clin. Vaccine Immunol., November 1, 2009; 16(11): 1595 - 1600. [Abstract] [Full Text] [PDF]

				M. Zhou, D. Xu, X. Li, H. Li, M. Shan, J. Tang, M. Wang, F.-S. Wang, X. Zhu, H. Tao, et al. Screening and Identification of Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific CTL Epitopes J. Immunol., August 15, 2006; 177(4): 2138 - 2145. [Abstract] [Full Text] [PDF]

				C. Biswas, U. Sriram, B. Ciric, O. Ostrovsky, S. Gallucci, and Y. Argon The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells Int. Immunol., July 1, 2006; 18(7): 1147 - 1157. [Abstract] [Full Text] [PDF]